DBV Technologies Plans Strategy For Peanut Allergy Debut In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The French biotech will set out its stall first in the U.S., where peanut allergy is a major concern, and plans to tackle the life-threatening condition with its transdermal patch without relying on local partners.